NLS Pharmaceutics to Merge with Kadimastem Ltd.
Ticker: NCEL · Form: 6-K · Filed: Nov 5, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Nov 5, 2024 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 13 min |
| Key Dollar Amounts | $600,000, $3,500,000, $0, $600,000 m, $10,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, acquisition, biotech
TL;DR
NLSP merging with KDST, deal inked Nov 4.
AI Summary
On November 4, 2024, NLS Pharmaceutics Ltd. (NASDAQ: NLSP) entered into an Agreement and Plan of Merger with its wholly owned subsidiary, NLS Pharmaceutics (Israel) Ltd., and Kadimastem Ltd. (TASE: KDST). This agreement outlines the terms for the merger between the two companies.
Why It Matters
This merger could significantly alter the corporate structure and strategic direction of NLS Pharmaceutics, potentially impacting its drug development pipeline and market position.
Risk Assessment
Risk Level: medium — Mergers inherently carry integration risks, regulatory hurdles, and potential market reception uncertainties.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant and party to merger agreement
- NLS Pharmaceutics (Israel) Ltd. (company) — Wholly owned subsidiary of NLS Pharmaceutics Ltd. and party to merger agreement
- Kadimastem Ltd. (company) — Party to merger agreement
- November 4, 2024 (date) — Date of the Agreement and Plan of Merger
FAQ
What is the primary purpose of the Agreement and Plan of Merger?
The Agreement and Plan of Merger outlines the terms and conditions for the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd.
When was the Agreement and Plan of Merger entered into?
The Agreement and Plan of Merger was entered into on November 4, 2024.
Which entities are involved in the merger agreement?
The entities involved are NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. (a subsidiary of NLS Pharmaceutics Ltd.), and Kadimastem Ltd.
What is the relationship between NLS Pharmaceutics Ltd. and NLS Pharmaceutics (Israel) Ltd.?
NLS Pharmaceutics (Israel) Ltd. is a wholly owned subsidiary of NLS Pharmaceutics Ltd.
What stock exchanges are the involved companies listed on?
NLS Pharmaceutics Ltd. is listed on NASDAQ (NLSP) and Kadimastem Ltd. is listed on TASE (KDST).
Filing Stats: 3,144 words · 13 min read · ~10 pages · Grade level 19.5 · Accepted 2024-11-05 08:00:30
Key Financial Figures
- $600,000 — t requires the Company to have at least $600,000 in cash at the Closing and requires Kad
- $3,500,000 — nd requires Kadimastem to have at least $3,500,000 in cash at the Closing, in each case su
- $0 — n the Merger Agreement) is greater than $0 and/or the Closing Cash (as defined in
- $600,000 m — ebtedness is $0 and the Closing Cash is $600,000 multiplied by (ii) 1.2. The Merger Agree
- $10,000,000 — pay to Kadimastem a termination fee of $10,000,000 plus the Company Operating Expenses (as
Filing Documents
- ea0219853-6k_nlspharma.htm (6-K) — 42KB
- ea021985301ex99-1_nlspharma.htm (EX-99.1) — 567KB
- ea021985301ex99-2_nlspharma.htm (EX-99.2) — 102KB
- ea021985301ex99-3_nlspharma.htm (EX-99.3) — 47KB
- 0001213900-24-094340.txt ( ) — 758KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: November 5, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 6